|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
 |
|
Download our eBook and discover everything you need to know about lipids for developing LNP therapies, including:….
|
|
 |
|
This guide outlines the fundamental considerations to ensure your CDMO selection aligns with your project goals.
|
|
 |
|
Nanoparticles are revolutionizing the landscape of nanomedicine, enabling significant advancements in early detection, targeted drug delivery, disease monitoring, and imaging. Due to their nanoscale size, these particles….
|
|
 |
|
Lyophilization, or freeze-drying, addresses stability challenges associated with complex APIs, biologics, microbiomes, gene therapies, viral vectors, liposomes, and nanoparticles……
|
|
|
|
|
|
|
|
|
Dr. Jens Frauenfeld, CEO, Salipro Biotech, and Dr. Francisco Ylera, R&D Team Lead at Bio-Rad Laboratories, explain how their collaboration is leveraging the Salipro® platform alongside Bio-Rad’s Pioneer™ Antibody Discovery Platform to target transmembrane proteins.
|
|
|
Johnny Peppers, PhD, and Christopher Mojcik, MD, PhD, explore the connection of obesity and inflammation, the current treatment landscape, and directions for future treatment.
|
|
|
Khursheed Anwer, PhD, MBA, and Douglas V. Faller, MD, PhD, highlight a new delivery system (TheraPlas®) being used to develop a more localized IL-12 immunotherapy for ovarian cancer and review its promising Phase 2 results.
|
|
|
Andrew Filachek says the ability to combine ideation and early stage development with materials science and process technologies has, in recent years, become a differentiator across a variety of device categories.
|
|
|
|
|
|
|
|
|

Douglas CDMO, based in New Zealand, has a history dating back to 1967. We offer end-to-end integrated drug development services, specializing in high-potency small molecule softgels, liquids, semi-solids, new chemical entities (NCEs), and branded generics. Our capabilities extend to manufacturing prescription drugs across key therapeutic areas, including oncology, dermatology, the central nervous system, and immunity. Working with clients across the globe, we pride ourselves on delivering superior quality and excellent service, ensuring our partners achieve successful, timely outcomes. Click here for more.
|
|
|
|
|
|
 |
|
Watch this on-demand webinar to learn about the key steps and considerations in bringing novel nanoparticle-based therapeutics from early R&D to commercial stages. Drawing from our 20 years of experience in the CDMO space, we cover critical topics unique to nanomaterials…..
|
|
 |
|
Tableting can present a series of challenges, particularly when dealing with formulations that have poor flowability, low compressibility, or high cohesivity. These issues can lead to manufacturing inefficiencies….
|
|
|
|
|
|
|
|
 |
|
By: Mark Rauckhorst, Director Supply Chain and Project Management, Vetter Development Service USA. Inc.
Clinical trials are high-visibility milestones for investors, as this is often the first major step toward financial return on what has likely been years of investment …
|
|
 |
|
While large molecules continue to advance in drug development pipelines, small molecule Active Pharmaceutical Ingredients (APIs) still retain their historical dominance among new drug applications (NDAs). However, the last few years have seen the lines blurring between traditional chemical synthesis …
|
|
 |
|
Honeywell Aclar® thermoformable film enables pharmaceutical and medical device companies to achieve their sustainability commitments.
Aclar® film not only delivers a high moisture barrier to protect medicines, but it also reduces pack size, reduces waste, and reduces carbon emissions, compared …
|
|
|
|
|
Upcoming eNewsletter Features:
May 14 – Capsules
May 21 – Injection Devices
|
|
|
|
|
|
|
|